Evidence map›Paper›PMID 28905323›Full record

ArticleInternational journal of hematology2018

Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.

Yukio Kobayashi, Wataru Munakata, Michinori Ogura, Toshiki Uchida, Masafumi Taniwaki, Tsutomu Kobayashi, Fumika Shimada, Masataka Yonemura, Fumiko Matsuoka, Takeshi Tajima and 2 more

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Yukio KobayashiDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan. ykkobaya@iuhw.ac.jp.ORCID http://orcid.org/0000-0003-2378-7865
Wataru MunakataDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Michinori OguraDepartment of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
Toshiki UchidaDepartment of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
Masafumi TaniwakiDepartment of Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tsutomu KobayashiDepartment of Hematology and Oncology, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Fumika ShimadaOncology Department, Novartis Pharma K.K., Tokyo, Japan.
Masataka YonemuraOncology Department, Novartis Pharma K.K., Tokyo, Japan.
Fumiko MatsuokaOncology Department, Novartis Pharma K.K., Tokyo, Japan.
Takeshi TajimaOncology Department, Novartis Pharma K.K., Tokyo, Japan.
Kimikazu YakushijinDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
Hironobu MinamiDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
Novartis (Japan) · JPJapanese Red Cross Nagoya Daini Hospital · JPKobe University Hospital · JPUniversity Hospital Kyoto Prefectural University of Medicine · JPNational Cancer Center · USTokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current therapy for high-risk myelodysplastic syndrome (MDS) involves repeated cycles of the DNA demethylating agent 5-azacitidine (5-Aza), but combination treatments have been proposed to improve patient outcomes. We performed a phase Ib study to investigate the safety and tolerability of 5-Aza (75 mg/m

Indexed as

AgedAsian PeopleAzacitidineDrug Administration ScheduleDrug Therapy, CombinationFemaleHistone Deacetylase InhibitorsHumansHydroxamic AcidsIndolesLeukemia, Myelomonocytic, ChronicMaleMiddle AgedMyelodysplastic SyndromesPanobinostatTreatment OutcomeAzacitidineHistone Deacetylase InhibitorsHydroxamic AcidsIndolesPanobinostatAMLAzacitidineCMMLMyelodysplastic syndromesPanobinostat

Identifiers

PMID28905323
OpenAlexW2755246038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.